Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress

Eur J Med Chem. 2022 May 20;238:114464. doi: 10.1016/j.ejmech.2022.114464. Online ahead of print.ABSTRACTAlzheimer's disease is a chronic and progressive brain neurodegenerative disease affecting over 30 million people globally. Currently, no effective treatment is available due to multiple factors involved in the progression of AD. Given that the numerous AD-related targets in the disease network, the multi-target-directed ligands (MTDLs) strategy are considered as the promising strategy to treat AD. Herein, the multi-target compounds with/without ChEs are in clinical and in progress are reviewed. To further characterize the drug-likeness, and ADME properties are calculated using the Qikprop. This review will provide highlights for the treatment of AD.PMID:35635955 | DOI:10.1016/j.ejmech.2022.114464

Source: European Journal of Medicinal Chemistry - May 31, 2022 Category: Chemistry Authors: Zhipei Sang Keren Wang Jianghong Dong Lei Tang Source Type: research